Purchase equipment or supplies - Government of British Columbia

Peace and SecurityOngoing and deadly Russian attacks across Ukraine are causing serious healthcare disruption, with more than $1.5 million-worth of medicines and supplies destroyed in four separate strikes on warehouses used by the UN there since July. According to the World Health Organization (WHO), 21 warehouses have been targeted this year, out of a total of 400 incidents, almost all involving heavy weapons which is classified as firearms, tanks, missiles, bombs and mortars.

HomeOverview The Sustainable Development GoalsMonitoring and Progress – HLPFFinancing for DevelopmentSustainable Development Goals Report 2026Decade of ActionThe 17 Goals 1-6Goal 1: No PovertyGoal 2: Zero HungerGoal 3: Good Health and Well-beingGoal 4: Quality EducationGoal 5: Gender equalityGoal 6: Clean Water and Sanitation7-12Goal 7: Affordable and Clean EnergyGoal 8: Decent Work and Economic GrowthGoal 9: Industry, Innovation and InfrastructureGoal 10: Reduced InequalitiesGoal 11: Sustainable Cities and CommunitiesGoal 12: Responsible Consumption and Production13-17Goal 13: Climate ActionGoal 14: Life Below WaterGoal 15: Life on LandGoal 16: Peace, Justice and Strong InstitutionsGoal 17: Partnerships for the GoalsGet Involved ActNow for the SDGsClimate Action SuperheroesActNow appThe Lazy Person’s Guide to Saving the WorldThe Lazy Person’s Guide to Saving WaterSDG Book ClubSDG Book Club | ArchiveYouthPartnerships About PartnershipsSDG Media CompactSDG Media ZoneSDG Publishers CompactSDG AdvocatesFootball For The GoalsSDG Circle of SupportersNews and Events Goal of the MonthGoal of the Month | ArchivePress materialsSDG Editorial CalendarNewsFeatured NewsVideosResources

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.